The effectiveness of mirtazapine in reducing dependence and the temptation to consume amphetamine and methamphetamine in patients
Phase 1
Recruiting
- Conditions
- Methamphetamine.
- Registration Number
- IRCT20230606058397N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
At least one positive urine test for methamphetamine during the hospitalization period
Absence of current acute illness
Absence of serious chronic diseases
Able and willing to provide informed consent and adhere to the visit schedule
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decreasing addiction in patients using amphetamine and methamphetamine. Timepoint: Before starting the treatment, at the beginning of the treatment and once every two weeks (the length of the treatment is 12 weeks), the results will be measured. Method of measurement: With physical examinations and measurement of vital signs, evaluation with the dependency index questionnaire.
- Secondary Outcome Measures
Name Time Method Reducing depression in patients using amphetamine and methamphetamine. Timepoint: Before starting the treatment, at the beginning of the treatment and once every two weeks (the length of the treatment is 12 weeks), the results will be measured. Method of measurement: with Beck depression questionnaire, physical examinations and measuring vital signs.